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Abstract 
 
This review highlights recently discovered antimalarial natural products from marine 
and freshwater sources described in the literature from 2006 to 2008. The structures 
as well as bioactivities of compounds against the malaria parasites such as 
Plasmodium falciparum are discussed, including for example agelasine, xestoquinone, 
alisiaquinone, crambescidin, venturamide, dragomabin, gragonamide, viridamide, 
salinosporamide, chaetoxanthone, nodulisporacid, tumonoic acid, girolline, oroidin, 
nostocarboline, aerucyclamide and microcylamide 7806 and its revised structure. 
Synthetic derivatives of natural products are presented including plakortin, 
isoaaptamine, curcuphenol, pseudopyronine, manzamine and nostocarboline. 
Consequences of these discoveries for the development of novel natural product 
agents against malaria are discussed. 
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Introduction 
 
Malaria constitutes the most threatening parasitic infection in humans. Each year, 
between 300 to 500 million new clinical cases are reported by the world health 
organization,1 resulting in annual deaths of about one million people,2 of which three-
quarters of the fatalities are children below 5 years of age.3 The most exposed 
continent is Africa, but also South-east Asia, Oceania, and Central and South America 
are under severe threat. Among the most affected countries are developing nations, 
which suffer from a weakly developed health care system.  
There are four species of Plasmodium infecting humans: P. falciparum, P. vivax, P. 
ovale and P. malariae, but most of the malaria cases are caused by the protozoan 
parasite P. falciparum.4 The parasite is transmitted by Anopheles mosquitos, and 
therefore malaria can be controlled to some extent by conventional prevention 
strategies such as mosquito repellents, mosquito traps, insecticides or biological 
control. The introduction of efficient vaccines is still problematic, despite recent 
progress in this area.5 As a direct consequence, the treatment of choice remains 
parasite chemotherapy with small molecule drugs both of natural origin or synthetics. 
6, 7 In parallel, resistance of the malaria parasite to commonly used drugs such as 
quinine, chloroquine and mefloquine is emerging,8 which results is an urgent need to 
develop new drugs against this disease. Also, an additional option for treatment, 
which implies reduction of the risk of resistance, offers the combination of two 
antimalarial drugs. Examples of such drug combinations are the artemisinin-
amodiaquine and the artemether-lumefantine combination (Coartem).9 
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Antiplasmodial Agents of Marine and Freshwater Origin 
 
The marine environment, taking more than 70% of the Earth’s surface, is a rich 
source of both biological and chemical diversity. As a consequence, such aqueous 
environments harbor new compounds with great potential as pharmaceuticals, 
nutritional supplements, cosmetics and agrochemicals.10 Many life forms in the 
marine environment such as algae, sponges, corals, ascidians and fungi have been 
investigated for their natural product content.11-13 Many structurally and 
pharmacologically important substances have been isolated with novel antimicrobial, 
antitumor, anti-inflammatory, antimalarial, antibiotic or antifouling properties, and 
they are described in several excellent reviews that have appeared in recent years.14-24  
In the current review, we give an overview of the bioactive metabolites recently 
isolated from marine organisms that have shown antiplasmodial activity and discuss 
their pharmacological potential. In addition, since some freshwater organisms have 
been found to populate both freshwater and marine environments (e.g. cyanobacteria), 
are found in brackish mixed environments, or are washed out into the ocean by rivers 
and streams, we have chosen to include examples from both aquatic domains. 
While we do not claim completeness, research efforts published between 2006 and 
2008 are discussed in the following chapters. 
 
Several alkaloids were identified from marine sources in the last years. A survey of 
different invertebrates was conducted by Mendiola et al.,25 in order to classify these 
sources for antiplasmodial activity. Seven extracts from different marine species, 
three species of Chordata, two species of Echinodermata, one species of Cnidaria and 
one species of Porifera, collected on the northwest Cuban coast from Havana to 
Puerto Esperanza were reported to display moderate antimalarial activity.25 Among 
them, three ascidians produced in vitro IC50 values lower than 30µg/ml, and in vivo, 
the crude extracts caused partial reduction of Plasmodium berghei parasitaemia in 
mice.25 Alkaloids and polyketides were found to be the major substances with 
antimalarial activity isolated from chordata, but the studied aqueous extracts of three 
ascidians were mixtures of compounds.  
Although agelasidae sponges have been widely investigated, they still represent a 
source of new marine metabolites.10 Three new diterpene alkaloids, agelasine J (1), 
agelasine K (2), and agelasine L (3), were recently isolated from the marine sponge 
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Agelas cf. mauritiana from the Solomon Islands.26a Agelasine J (1) was obtained 
previously by Nakamura et al. by semisynthesis from agelasine A or B under acidic 
conditions.26b All three compounds displayed moderate activity on P. falciparum with 
IC50 = 6.6, 8.3 and 18 µM for agelasines J, K and L, respectively, and a low 
cytotoxicity on MCF7 cells with IC50 values of 33, 30 and 80 µM, was determined. 
The molecular target of these substances was not yet investigated.26a 
 
  
 
From a Mycophora sp. Sponge, crambescidin 800 (4) was isolated,27 which had been 
previously reported,28 and few analogues had been prepared. Crambescidin 800 (4) 
showed in vitro activity against chloroquine(CQ)-resistant FCR3 P. falciparum (IC50 
= 240 nM) and CQ-sensitive 3D7 strains, (IC50 = 160 nM). The most active analogue 
5 had in vitro activity against P. falciparum strain 3D7 comparable to quinine as well, 
but slightly less than that of crambescidin 800 (IC50 = 490 nM). 27 The mode of action 
has not been investigated, but similar compounds have been shown to be channel 
blockers or ATPase inhibitors.27 
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Novel isoaaptamine analogues29 were prepared by coupling acyl halides to the C9 
position of isoaaptamine (6), first isolated from a sponge of the genus Suberites by 
Fedoreev,30 later by two other groups from the sponge Aaptos aaptos,31, 32 and 
recently from a sponge belonging to the genus Hymeniacidon.33 The compound 6 
displayed remarkable activity against the W2 clone and good activity against the D6 
clone of P. falciparum, with an IC50 values of 380 and 1100 ng/mL, respectively. All 
nineteen synthesized derivatives resulting from various acyl halides coupled at C9 
position of isoaaptamine (6) have had a negative impact on the activity against the 
W2 clone. However, the activity against the D6 clone in many derivatives increased, 
and the most potent were compounds 7 and 8, with IC50 = 230 and 240 ng/mL, 
respectively.29 
 
   
Recently Tasdemir et al.34 reported isolation of six pure metabolites and some 
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complex fatty acid mixtures (FAMA-FAMG) from the Turkish marine sponge Agelas 
oroides which showed promising PfFabI inhibitory and antiplasmodial activity. 
Among the metabolites, (E)-oroidin (9) was isolated as free base and identified as the 
most potent enzyme PfFabI inhibitor with IC50 = 0.77 µM. The kinectic analysis 
revealed an uncompetitive binding mechanism with respect to substrate and cofactor, 
indicating that the compound 9 is exclusively binding to the enzyme-substrate 
complex or enzyme-cofactor complex.34 This mechanism is identical to the one 
observed for triclosan towards FabI of various species.35, 36 Oroidin base (9) was 
assayed for its in vitro inhibitory activity on multidrug resistant K1 strain of P. 
falciparum and it exhibited an IC50 value of 3.9 µg/mL in the whole cell parasite 
assays. Oroidin (9) is a condensation product of the imidazol portion, 3-amino-1-(2-
aminoimidazoyl)-prop-1-ene (10), which has no effect on PfFabI, but has unspecific 
effect on the malaria parasite, and 4,5-dibromopyrrole-2-carboxylic acid 11, which is 
not toxic, but has limited antimalarial and PfFabI inhibition activities. A previous 
report37 described oroidin (as TFA salt) to be inactive towards the D6 and W2 strains 
of P. falciparum, however, a more recent study reported a moderate antimalarial 
effect with an IC50 = 1.2 µg/mL.38 
  
 
  
 
Benoit-Vical and co-workers39 evaluated the effects of a natural product girolline (12) 
and some of its synthetic analogues in vitro and in vivo against P. falciparum and P. 
vinckei petteri, respectively. This 2-aminoimidazol derivative was originally isolated 
from a New-Caledonian sponge Cymbastela cantharella,40 and this compound was 
demonstrated for its antitumor properties.41-43 More recently the compound 12 has 
been also isolated from another species of the marine sponge Axinella brevistyla 
collected in western Japan.44 
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The IC50 value of girolline (12) on the CQ-resistant strain FcM29 was determined to 
be 130 nM, and with artemisinin or chloroquine the compound inhibited parasitic 
growth by 100%. Several synthetic analogues were shown to possess IC50 values 
higher than 50 µM. Girolline (12) showed also very high activity in an in vivo 
Plasmodium vinckei petteri assays, and even although the compound displays some 
toxicity,42 it might considered as a natural compound with very promising activity 
against malaria.39 The mode of action of this compound is debated in the literature, 
and Benoit-Vical et al. suggest its mechanism to be related to the inhibition of protein 
synthesis.39 
 
Our group has recently isolated nostocarboline (13), an acetyl- and butyryl-
cholinesterase, and trypsin inhibitor from the cyanobacterium Nostoc 78-12A.45-47 The 
compound itself inhibits Plasmodium with high selectivity in nanomolar 
concentrations, and additionally, dimerization of nostocarboline leads to very potent 
and selective antiplasmodial agents.48 Nostocarboline (74) was synthesized starting 
from norharmane via chlorination at C-6 and methylation according to published 
procedures.45, 46 
 
Scheme 1. Preparation of nostocarboline (13) from norharmane. Reagents and 
conditions: (a) NaOCl, EtOH, 0 °C, 30 min, then rt, 5 h, 75%; (b) CH3I, i-PrOH, 
reflux, 4 h, 94%.  
 
     
 
6-Cl-norharmane was also the starting material for the synthesis of ten nostocarboline 
symmetrical homo-dimers of general formular 14. Alkenyl, alkynyl, aryl, biaryl and 
alkyl linkers of various lenghts were employed for the corresponding dimers, which 
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were obtained in a two-step process and in good yields (60 – 95%). 
Nostocarboline (13) as well as dimers such as 16-20 were evaluated against P. 
falciparum K1. Nostocarboline (13) displayed antimalarial activity against the K1 
strain with an IC50 = 194 nM, and in addition it showed very weak cytotoxicity (>100 
µM), giving rise to a 600 fold selectivity of Plasmodium over rat myoblast L6 cells. 
The best results against P. falciparum were obtained for dimers with long and flexible 
linkers, and compounds 16-20 displayed IC50 values below 100 nM, and the most 
active compound 19 containing a (CH2)10 linker displayed an IC50 = 14 nM against P. 
falciparum K1. Cytotoxicity against the L6 rat myoblast cell line was determined as 
well, and the values varied between 5-60 µM. Cytotoxicity increased with linker 
length, thus decreasing selectivity for longer linkers. Compounds 16 and 17 with five 
and six atom linkers are considered optimal in this series. Compound 16 displayed 
high potency (IC50 = 18 nM) and an excellent selectivity of >2500-fold against the L6 
cell line. The mode of action of these compounds is currently under investigation. 
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A remarkable example of a marine compound with potential activity against P. 
falciparum is manzamine A (21), a unique beta-carboline alkaloid. The compound 
was first isolated from the Okinawan sponge of the genus Haliclona,49 since then 
more than 60 manzamine and related alkaloids have been isolated from 16 species of 
sponges belonging to nine different genera.50, 51 More than 90% of the asexual 
erythrocytic stages of Plasmodium berghei were inhibited after a single 
intraperitoneal injection of manzamine A (21) into infected mice. Such suppressive 
activity is comparable to that of chloroquine and superior to that of artemisinin at the 
same dose.52 
One of the common manzamine alkaloids is 8-hydroxy-manzamine A (22) that has 
been isolated from sponges of the genera Amphimedon, Xestospongia, 
Acanthostrongylophora, and Pachypellina. 53-55 Despite highly promising antimalarial 
activity, toxicity remains a major problem with respect of the potential for alkaloids 
such as  21 and 22 as drugs. 
 
   
 
Three acetylated 8-hydroxymanzamine A (22) analogues 23, 24 and 25 were prepared 
by modification at the 8-position in an effort to generate manzamine prodrugs with 
improved antimalarial activity and reduced GI toxicity.56 These synthetic analogues 
exhibited antimalarial activity against the chloroquine-sensitive (D6) and the 
chloroquine-resistant (W2) strains of Plasmodium falciparum with values ranging 
from 9 to 1300 ng/mL. The most significant in vitro antimalarial activity displayed 
analogue 23, with an IC50 = 9.6 ng/mL against the D6 strain, and IC50 = 30 ng/mL 
against the W2 strain, what is comparable to 8-hydroxymanzamine A (22). Analogue 
24, which contains acetoxy groups at both the 8- and 12-positions, was the least 
potent compound, with IC50 values of 1300 and 1200 ng/mL against the D6 and W2 
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clones, respectively. Analogues 23 and 25 exhibited toxicity to the normal Vero cell 
line, while the diacetate 24 did not show cytotoxicity at the highest tested 
concentration of 4700 ng/mL. Analogue 23 was also evaluated for in vivo antimalarial 
activity against Plasmodium berghei sensitive strain, but appeared being rather 
toxic.56 Interesting results of quaternary manzamine derivatives similar to 
nostocarboline (13) were reported.57 All these examples 1-25 support the notion that 
alkaloids still represent an important class for the discovery of novel antimalarial 
agents. 
 
 
   
 
 
Several peptides were isolated over the last years that display antiplasmodial activity. 
Gerwick and coworkers have recently isolated antimalarial venturamides A (26) and 
B (27) from a Panamanian Oscillatoria sp..58 These modified cyclic hexapeptides 
showed moderate selectivity for the parasite versus mammalian host cells. 
Venturamide A (26) showed in vitro activity against P. falciparum (IC50 = 8.2 µM), 
with only mild cytotoxicity to mammalian Vero cells (IC50 = 86 µM). Venturamide B 
(27) also showed low micromolar antimalarial activity against P. falciparum (IC50 = 
5.6 µM) and mild cytotoxicity to mammalian Vero cells (IC50 = 56 µM). The mode of 
action of these compounds is yet unknown. 
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Four new haxacyclopeptides, aerucyclamides A59 (28), B 59 (29), C 60  (30) and D 60 
(31) were isolated from cyanobacterium Microcystis aeruginosa PCC 7806 and their 
structural characterization, synthesis and biological evaluation have been reported. 59, 
60 These peptides are the actual metabolites produced by ribosomal peptide synthesis 
in M. aeruginosa PCC 7806, it has been predicted by a parallel study.61 
 
  
 
Aerucyclamide A (28) is a rare example of a cyclamide that features oxazoline, 
thiazoline, and thiazole moieties in one compound. Aerucyclamide B (29) is an 
oxidative derivative of 28, and can be obtained synthetically through oxidation of 
aerucyclamide A (28) (MnO2, benzene). Surprisingly, the structure of aerucyclamide 
14 
C (30) matched the one reported for microcyclamide 7806A (32) despite different 
data. Structure 32 was postulated as the actual metabolite of ribosomal peptide 
synthesis by Ziemert et al.61 Therefore, we suggested a structure revision of 
microcyclamide 7806A (32),60 based on chemical, physical and spectroscopic 
evidence. The revised structure 33 for microcyclamide 7806A60 includes an ester 
involving the Thr group and the ammonium residue instead of the oxazoline ring. 
Moreover, microcyclamides 7806A (32) and B (34) can be obtained under acidic 
conditions frequently used in HPLC purifications (CF3CO2H in H2O) from 
aerucyclamide C (30). This chemical transformation supports the hypothesis that both 
microcyclamides 7806A (32) and B (34) are isolation artifacts, and that the 
aerucyclamides A-D (28-31) are the actual metabolites produced via ribosomal 
peptide synthesis in Microcystis aeruginosa PCC 7806.60 
 
All four cyclamide derivatives 28-31 were biologically evaluated for antiplasmodial 
activity. The most active compound was aerucyclamide B (29), displaying a 
submicromolar IC50 value of 0.7 µM against the chloroquine-resistant strain K1 of 
Plasmodium falciparum. In addition, this compound displays a large selectivity for 
the parasite with respect to the L6 rat myoblast cell line, where an IC50 value of 120 
µM was determined. Interestingly, a reduction of the thiazole to a thiazoline 
(structural modification from 29 to 28) decreases the antiplasmodial activity by 1 
order of magnitude. Similar low micromolar activities displayed aerucyclamides C 
(30) and D (31) (IC50 = 2.3 and 6.3 µM, respectively). All compounds displayed very 
weak (for 29 and 30) or no toxicity to the L6 rat myoblast cell line under the 
conditions evaluated. Therefore, such cyclamides 28-31 as well as venturamides A 
(26) and B (27) can be considered interesting lead structures for further development. 
 
Gerwick and coworkers reported two other marine cyanobacterial metabolites.62 New 
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linear alkynoic lipopetides, dragomabin (35) and dragonamide B (36), have been 
isolated from a red Panamanian strain of the marine cyanobacterium Lyngbya 
majuscula from different sites in the Bocas del Toro region.62 
 
  
 
Dragomabin (35) showed good antimalarial activity (IC50 = 6 µM) against 
chloroquine-resistant Plasmodium falciparum, whereas the nonaromatic analogue, 
dragonamide B (36) was inactive in this assay.   
An investigation of a marine cyanobacterium Oscillatoria nigro-viridis from Panama 
led to the isolation of two novel bioactive lipopeptides, viridamides A (37) and B 
(38).63 Viridamide A (37) was tested against a series of relevant tropical pathogens 
and cancer cell lines, and it displayed significant activity against the parasitic 
protozoan P. falciparum (IC50 = 5.8 µM), but also displayed strong activity against 
Trypanosoma cruzi and Leishmania mexicana. 
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The marine cyanobacterium Blennothrix cantharidosmum was a source for six new 
acyl proline derivatives, tumonoic acids D-I (39-44), plus the known tumonoic acid A 
and lyngbyastatins as the active metabolites.64 The tumonoic acids were originally 
isolated from a Lyngbya majuscula / Schizothrix calcicola assemblage, as well as 
collection of L. majuscula, all collected in Guam,65 but phylogenetic investigation 
using 16S rRNA suggests that these compounds could also originate from 
Lyngbya/Blennothrix assemblages. The new compounds were tested in an array of 
assays, but only tumonoic acid I (44) displayed antimalarial activity with an IC50 = 2 
µM, none of the other naturally occurring analogues showed any activity in this assay 
at a concentration of up to10 µg/mL. The target of these compounds is unknown.64 
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In addition to these peptides, several amino acid derivatives were isolated and 
characteriyed. Salinosporamide A (45) was initially discovered and described in 2003 
by Fenical and co-workers from the marine actinomycete Salinispora tropica66 and 
belongs to a family of compounds possessing a densely functionalized γ-lactam-β-
lactone bicyclic framework. These compounds are potent anticancer agents due to 
proteasome inhibition. Compound 45 was evaluated by Prudhomme et al.,67 who 
found this lactam 45 to be a highly potent inhibitor of the human malaria parasite both 
in vitro (IC50 = 11.4 nM) and in vivo (ca. 90 % reduction in parasitemia at 130 µg/kg 
(s.c.) in mice,  P. yoelii). More promisingly, salinosporamide A (45) is currently in 
phase I clinical trials against the treatment of refractory multiple myeloma. 
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Eight compounds, including four new natural products, were isolated from the marine 
octocoral Muricea austera collected in the Pacific coast of Panama.68 Two natural 
tyramine derivatives, 46 and 47, showed moderate antiplasmodial activity  (IC50 = 45 
and 38 µM), and a series of synthetic derivatives with fatty acid moieties showed 
antiplasmodial activity very similar to those of their natural analogues.68  
  
  
 
 
Another class of natural products with antiplasmodial activity encompasses 
hydroxyaromatic compounds. Three new natural products chaetoxanthones A (48), B 
(49) and C (50) were isolated from marine-derived fungus Chaetomium sp..69 
Compounds 48 and 49 are substituted with a dioxane/tetrahydropyran moiety rarely 
found in natural products, and compound 50 was identified as a chlorinated xanthone 
substituted with a tetrahydropyran ring. The new xanthones were tested in a series of 
in vitro bioassays for their antiprotozoal activities and cytotoxic potency. Among the 
isolated xanthones only chaetoxanthone B (49), which was probably isolated as 
racemate based on CD spectroscopic evidence, showed selective antiprotozoal 
activity against P. falciparum with an IC50 = 0.5 µg/mL (at least 7.5-fold enhanced 
potency compared to the other tested protozoans) without being cytotoxic toward 
cultured eukaryotic L6-cells (IC50 > 90 µg/mL). The mode of action of xanthones 
toward Plasmodium parasites was investigated in detail in earlier studies,70, 71 and 
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these compounds are considered to inhibit heme polymerization. Thus, the 
detoxification of harmful hematin is hampered which results in the death of the 
parasitic cells.70, 71 
 
  
Previously described xestoquinone72-80 (51) was re-isolated from the marine sponge 
Xestospongia collected in Vanuatu in South Pacific.36 The selectivity of the protein 
kinase inhibitory activity of xestoquinone against a panel of P. falciparum protein 
kinases was evaluated.81 Xestoquinone (51), the most potent and the most abundant 
Pfnek-182 inhibitor, showed a moderate in vitro antiplasmodial activity against a 
FCB1 P. falciparum strain (IC50 = 3 µM) and exhibited a cytotoxic activity on MCF7 
cells with an IC50 value of 20 µM, but it only exhibited weak in vivo activity at 5 
mg/kg in Plasmodium berghei NK65 infected mice and was toxic at higher doses. 
 
  
 
Four new bioactive compounds, alisiaquinones A, B and C (52, 53 and 54) and 
alisaquinol (55), were isolated from a New Caledonian deep-water sponge.83 They are 
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related to xestoquinone (51),76, 84 methoxyxestoquinone,79 adociaquinone80 and 
xestoquinol,39, 76, 84 respectively, but show an unusual substitution pattern on the furan 
ring. These new meroterpenes displayed mild activity with micromolar range on two 
enzymatic targets of importance for the control of malaria, the plasmodial kinase 
Pfnek-1 and a protein farnesyl transferase (PFT) as well as on different chloroquine-
sensitive and chloroquine-resistant strains of Plasmodium falciparum.83 
Alisiaquinones A (52) and B (53) and alisiaquinol (55) displayed similar activities in 
vitro on Plasmodium falciparum, but the IC50 values were not determined on Pfnek-1. 
Alisiaquinone A (52) was slightly less cytotoxic and had low selectivity index. 
Alisoquinone C (54), bearing the taurine substituent, displayed a submicromolar 
activity on Plasmodium falciparum and a competitive selectivity index on the 
different plasmodial strains, especially on the chloroquine-resistant strain PfFcMC29. 
For alisaquinones A (52) and C (54) also the in vivo activity was investigated, but 
they displayed a relatively high level of toxicity. 
 
  
A new tetronic acid, nodulisporacid A (56), isolated from a marine-derived fungus 
Nodulisporium sp. CRIF1 exhibited moderate antiplasmodial activity.85 This 
compound was identified as a truncated derivative of lowdenic acid86 and a known 
tetramic acid, vermelhotin (59), obtained from an unidentified fungus CRI247-01 (a 
member of the order Pleosporoles),85 and was previously obtained as a single E-
isomer from another unidentified fungus.87 Both compounds 56 and 59 revealed 
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spontaneous inter-conversion between E- and Z-isomers, forming an equilibrium E/Z 
mixture with the ratio of 1:1 for nodulisporacid A (56) and 1:2 for vermelholtin (59).  
Nodulisporacid A (56), the two synthetic derivatives (57 and 58), as well as 
vermelhotin (59) exhibited good antiplasmodial activity with IC50 values between 1-
10 µM, with the latter compound displaying moderate cytotoxicity.85 Previously, 
vermelhotin (59) was tested against fungi and bacteria, but it showed no antifungal 
and antibacterial activities.87  
 
  
 
  
Natural products are prime candidates for the synthesis of analogues, which might be 
more effective and less toxic than the parent natural products. A series of 
semisynthetic derivatives88 of a remarkably simple 1,2-dioxane derivative, plakortin 
(60) was prepared. Plakortin (60) itself was isolated from the Caribbean sponge 
Plakortis simplex, and together with its 9,10-dihydro analogue 61, and two other 
analogues 3-epiplakortin (62) and plakortide Q (63) display submicromolar activities 
in vitro against chloroquine-resistant strains of P. falciparum.89-91 
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The authors88 confirmed the crucial role of the endoperoxide functionality in the 
antimalarial activity of plakortin derivatives, since diol (64) was completely 
ineffective. The reduction of the ester function to the corresponding hydroxy (65), 
methoxy (66) or acetoxy (67) derivatives did not affect activity and selectivity for the 
tested strains of Plasmodium falciparum. A much more pronounced effect on the 
antimalarial activity are imparted by changes on the alkyl side chain.88 
 
 
  
 
The biologically active marine sesquiterpene phenol (S)-(+)-curcuphenol (68) has 
been isolated from the Jamaican sponges Didiscus oxeata, Didiscus flavus, 
Myrmekioderma styx and Epipolasis sp.92-94 The compound display in vitro 
antimalarial activity against P. falciparum, chloroquine-resistant W2 clone, with an 
IC50 = 16.5 µM,92 but it has no antimalarial activity against the chloroquine-sensitive 
D6 clone.  
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Hamann et al.95 reported the preparation and evaluation for activity against several 
infectious diseases, of twenty semisynthetic analogues of (S)-(+)-curcuphenol (68). 
They were prepared in yields greater than 90% by esterification of (S)-(+)-
curcuphenol (68) with a variety of carboxylic acids in a presence of N,N`-
dicyclohexylcarbodiimide (DCC) or 4-dimethylaminopyridine (DMAP). There was 
significant increase in activity against W2 clones in nine analogues of general 
structure 69 and IC50 = 1.6  µM for 70 and 71 was measured, but no increase in 
activity against the D6 clone was observed.  
 
   
 
Total syntheses of the 2-pyrone-containing marine microbial metabolites 
pseudopyronines A (72) and B (73), recently reported as weak antibiotics,96, 97 as well 
as a number of analogues have been achieved via a methodology based upon the 
condensation of β-oxo carboxylic acids.98 The compounds 72 and 73 were originally 
isolated from fermentation of Pseudomonas sp. F92S91, which was itself isolated 
from a sponge collected in Fiji.  
 
  
 
Fatty acids (FAs) are essential for all living organisms, they play crucial roles in the 
function and viability of cells providing components for biological membranes, acting 
as chemicals messengers and facilitating the storage of energy. Both natural products, 
72 and 73, inhibited PfFabI, the enoyl-ACP-reductase of P. falciparum with IC50 = 12 
and 4 µg/mL, respectively and additionally pseudopyronine B (72) inhibited PfFabG, 
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a β-ketoacyl-ACP-reductase. The enzyme inhibitory activities of compounds 72 and 
73 were well correlated with their in vitro growth inhibitory potential on P. 
falciparum whole cells, providing evidence that the PfFab pathway may be the 
potential cellular target of these compounds.98 
Several carbohydrates or glycosylated structures were also reported in the literature. 
Glycosides 74 and 77, showed moderate antiplasmodial activity (IC50 = 67 and 80 
µM), which could be somewhat increased in the triacetylated derivative 76 (IC50 = 28 
µM).68 
  
 
The same authors68 synthesized and evaluated the antiplasmodial activity of a series 
of arabinopyranosides, where two compounds, 77 and 78 (IC50 = 35 and 21 µM), were 
found to be active against Plasmodium falciparum, and were found being more active 
than the natural arabinopyranosides 74 and 75. Antiplasmodial activity was also 
reported for simple sugar derivatives, with the same configuration as that of D-
arabinopyranose, such as the D-fucosides 79 and 80 (IC50 = 43 and 36 µM) and D-
galactoside 81 (IC50 = 21µM). 
 
  
 
 
A new antimalarial polyether type metabolite 82 was isolated from the marine 
microorganism Streptomyces sp. H668.99 The antimalarial activity of 28 was 
25 
evaluated against both the chloroquine-susceptible (D6) and chloroquine-resistant 
(W2) clones of P. falciparum. Compound showed in vitro antiprotozoal activity with 
IC50 values ranging from 100 to 200 ng/mL without significant cytotoxicity to Vero 
cells. The polyether metabolite 82 is also rather specific to the parasite displaying no 
toxicity at 4.75 µg/mL. 
 
  
 
 
 
Conclusion 
 
The present review highlighted various efforts on antimalarial agents that have been 
documented over the last three years thus clearly demonstrating the high scientific 
activity of the field. Many new interesting lead structures have been discovered, and 
valuable structure/activity information has been gathered through total or semi-
synthesis. Some compounds are currently evaluated in the clinic, and it is hoped that 
more efficient marine natural products will join the fight against malaria in the future. 
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